RAMOS, C.; MONTAÑO, E.; REYES-LÓPEZ, A.; LEMUS, F.; PACHECO, M.; HERNANDEZ, G.; LEMUS, A. Economic evaluation of lenalidomide (Revlimid®) for the treatment of mielodysplastic syndrome with 5q deletion at low/intermediate-1 risk: Evaluación Económica de Lenalidomida (Revlimid®) Para el Tratamiento Del Síndrome Mielodisplásico Con Deleción 5q de Riesgo Bajo/Intermedio-1. Global and Regional Health Technology Assessment, [S. l.], v. 4, n. 1, p. 133–140, 2019. DOI: 10.33393/grhta.2017.387. Disponível em: https://journals.aboutscience.eu/index.php/grhta/article/view/387. Acesso em: 3 jul. 2024.